BIOMAT Database Logo BIOMAT Database Logo

Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. 2007

Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Key Laboratory of Laboratory Medical Diagnostics of Ministry of Education, Department of Laboratory Medicine in Chongqing Medical University, Chongqing 400016, PR China.

Immunization with a combination of several virulence-associated proteins is one of the strategies of developing effective protein-based vaccines to enhance the protection against Streptococcus pneumoniae. In this study, we evaluated the protection effects against pneumococcal infection caused by S. pneumoniae TIGR4 in BALB/c mice immunized with either single pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC), the caseinolytic protease (ClpP) or their combinations. The median survival times for mice immunized with single antigen or their combinations were significantly longer than that for mice treated with adjuvant alone. Mice treated with a combination of three antigens survived significantly longer than those that received either single or two antigens. The highest survival rate of the various groups of mice was observed with the combination of three antigens, this survival rate was significantly different from those for mice that received either single antigen or the combinations of two antigens except the mixture of ClpP and PspA. In the experiment of passive immunization with hyperimmune serums containing their specific polyclonal antibodies (anti-PspA serum, anti-PspC serum, anti-ClpP serum), the median survival times for mice immunized with hyperimmune serums containing specific polyclonal antibodies were significantly longer than that for control mice, the treatment of serum containing only one single polyclonal antibody could not provide higher survival rate than control serum. However, the survival rates for mice treated with the serums containing combined polyclonal antibodies were significantly higher than those for mice treated with either control serum or anti-PspA serum alone. Immunization with the combination of three hyperimmune serums also provided the best protection against S. pneumoniae. Compared to mice treated with serum containing single polyclonal antibody, the survival rate for mice treated with serums containing three polyclonal antibodies was significantly higher but was not different from those for mice treated with serums containing two polyclonal antibodies. Our findings provided evidence that a mixture of PspA, PspC, and ClpP or their polyclonal antibodies could enhance the protection against pneumococcal infection acting a synergetic effect.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011008 Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE. Streptococcus pneumoniae Infections,Infections, Pneumococcal,Infections, Streptococcus pneumoniae,Pneumococcal Diseases,Disease, Pneumococcal,Diseases, Pneumococcal,Infection, Pneumococcal,Infection, Streptococcus pneumoniae,Pneumococcal Disease,Pneumococcal Infection,Streptococcus pneumoniae Infection
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D012697 Serine Endopeptidases Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis. Serine Endopeptidase,Endopeptidase, Serine,Endopeptidases, Serine
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus

Related Publications

Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Protection against pneumococcal infection elicited by immunization with multiple pneumococcal heat shock proteins.
August 2013, Vaccine,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA).
December 2008, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
October 2018, Microbial pathogenesis,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection.
January 2018, PloS one,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Human antibody response towards the pneumococcal surface proteins PspA and PspC during invasive pneumococcal infection.
January 2007, Vaccine,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
July 2006, Vaccine,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.
May 2009, Clinical and vaccine immunology : CVI,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1.
April 2014, Journal of microbiology (Seoul, Korea),
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
Protection against pneumococcal infection elicited by immunization with glutamyl tRNA synthetase, polyamine transport protein D and sortase A.
May 2012, Vaccine,
Ju Cao, and Dapeng Chen, and Wenchun Xu, and Tingmei Chen, and Songxiao Xu, and Jingyong Luo, and Qing Zhao, and Beizhong Liu, and Dongsheng Wang, and Xuemei Zhang, and Youlan Shan, and Yibing Yin
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.
February 2000, Vaccine,
Copied contents to your clipboard!